NorthWest Biotherapeutics Inc (NWBO)

[Umibe5690]

Doc:

I tend to agree that the crossovers in this trial probably did not benefit except perhaps to a minor degree. However, suppose that there is more than minimal benefit to the crossovers. While it may not be good for the trial it would suggest the very broad and powerful efficacy of DC VAX L extending to recurrent GBM despite the fact that very few crossover patients had a second resection. This would be a good thing.